Loracarbef: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
mNo edit summary
 
mNo edit summary
Line 1: Line 1:
{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 462093698
| IUPAC_name = (6''R'',7''S'')-7-<nowiki>[[</nowiki>(2''S'')-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
| image = Loracarbef.png
<!--Clinical data-->
| tradename = Lorabid
| Drugs.com = {{drugs.com|monograph|loracarbef}}
| MedlinePlus = a601206
| pregnancy_category = 
| legal_status = 
| routes_of_administration = 
<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 25%
| metabolism = 
| elimination_half-life = 
<!--Identifiers-->
| CASNo_Ref = {{cascite|changed|??}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 76470-66-1
| ATC_prefix = J01
| ATC_suffix = DC08
| PubChem = 5284584
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00447
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4447634
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = W72I5ZT78Z
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08143
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1013
<!--Chemical data-->
| C=16 | H=16 | Cl=1 | N=3 | O=4
| molecular_weight = 349.769 g/mol
| smiles = Cl\C3=C(/C(=O)O)N2C(=O)[C@@H](NC(=O)[C@@H](c1ccccc1)N)[C@H]2CC3.O
| InChI = 1/C16H16ClN3O4.H2O/c17-9-6-7-10-12(15(22)20(10)13(9)16(23)24)19-14(21)11(18)8-4-2-1-3-5-8;/h1-5,10-12H,6-7,18H2,(H,19,21)(H,23,24);1H2/t10-,11-,12+;/m1./s1
| InChIKey = GPYKKBAAPVOCIW-HSASPSRMBZ
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C16H16ClN3O4.H2O/c17-9-6-7-10-12(15(22)20(10)13(9)16(23)24)19-14(21)11(18)8-4-2-1-3-5-8;/h1-5,10-12H,6-7,18H2,(H,19,21)(H,23,24);1H2/t10-,11-,12+;/m1./s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}= {{stdinchicite|correct|chemspider}}= {{stdinchicite|correct|chemspider}}
| StdInChIKey = GPYKKBAAPVOCIW-HSASPSRMSA-N
}}
__NOTOC__
__NOTOC__
{{CMG}}
==Overview==
Loracarbef is an [[antibiotic]].<ref name="pmid8150976">{{cite journal |author=Biedenbach DJ, Jones RN |title=Predictive accuracy of disk diffusion test for Proteus vulgaris and Providencia species against five newer orally administered cephalosporins, cefdinir, cefetamet, cefprozil, cefuroxime, and loracarbef |journal=J. Clin. Microbiol. |volume=32 |issue=2 |pages=559–62 |year=1994 |month=February |pmid=8150976 |pmc=263078 |doi= |url=http://jcm.asm.org/cgi/pmidlookup?view=long&pmid=8150976}}</ref> Its use was discontinued in 2006.{{fact|date=January 2011}} It is a [[carbacephem]], but it is sometimes grouped together with the second-generation [[cephalosporin]] antibiotics. It was marketed under the trade name Lorabid.
Loracarbef is a synthetic "carba" analogue of cefaclor, and is more stable chemically. Diarrhea is the most common adverse effect with Loracarbef. Side effects are more frequently seen with children under the age of twelve. It received FDA approval in 1991.
==Category==
Carbacephem
==US Brand Names==
LORABID<sup>®</sup>
==Mechanism of Action==
==References==
{{Reflist|2}}
==External links==
* [http://www.rxlist.com/cgi/generic/loracarb.htm RxList.com - Loracarbef]
[[Category:Antibiotics]]
[[Category:Wikinfect]]

Revision as of 03:19, 31 December 2013

Loracarbef
Clinical data
Trade namesLorabid
AHFS/Drugs.comMonograph
MedlinePlusa601206
ATC code
Pharmacokinetic data
Protein binding25%
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC16H16ClN3O4
Molar mass349.769 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Loracarbef is an antibiotic.[1] Its use was discontinued in 2006.[citation needed] It is a carbacephem, but it is sometimes grouped together with the second-generation cephalosporin antibiotics. It was marketed under the trade name Lorabid.

Loracarbef is a synthetic "carba" analogue of cefaclor, and is more stable chemically. Diarrhea is the most common adverse effect with Loracarbef. Side effects are more frequently seen with children under the age of twelve. It received FDA approval in 1991.

Category

Carbacephem

US Brand Names

LORABID®

Mechanism of Action

References

  1. ↑ Biedenbach DJ, Jones RN (1994). "Predictive accuracy of disk diffusion test for Proteus vulgaris and Providencia species against five newer orally administered cephalosporins, cefdinir, cefetamet, cefprozil, cefuroxime, and loracarbef". J. Clin. Microbiol. 32 (2): 559–62. PMC 263078. PMID 8150976. Unknown parameter |month= ignored (help)

External links

Retrieved from "https://www.wikidoc.org/index.php?title=Loracarbef&oldid=921781"